Author:
Chen Shaohua,Wang Guan,Niu Xiaojia,Zhao Jianyun,Tan Wenxi,Wang Hebin,Zhao Lijing,Ge Yubin
Reference47 articles.
1. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial;Audeh;Lancet,2010
2. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair;Bolderson;Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res.,2009
3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol.,1997
4. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies;Chou;Pharmacol. Rev.,2006
5. Bax and Bid, two proapoptotic Bcl-2 family members, inhibit homologous recombination, independently of apoptosis regulation;Dumay;Oncogene,2006
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献